×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
SLNO – soleno therapeutics, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
SLNO
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
4/3
06:01 am
slno
Soleno Therapeutics, Inc. (NASDAQ: SLNO) was given a new $105.00 price target on by analysts at UBS Group AG.
Low
Report
Soleno Therapeutics, Inc. (NASDAQ: SLNO) was given a new $105.00 price target on by analysts at UBS Group AG.
3/31
08:16 am
slno
Soleno Therapeutics, Inc. (NASDAQ: SLNO) had its price target raised by analysts at HC Wainwright from $70.00 to $100.00. They now have a "buy" rating on the stock.
Low
Report
Soleno Therapeutics, Inc. (NASDAQ: SLNO) had its price target raised by analysts at HC Wainwright from $70.00 to $100.00. They now have a "buy" rating on the stock.
3/28
10:57 am
slno
Soleno Therapeutics, Inc. (NASDAQ: SLNO) had its price target raised by analysts at Stifel Nicolaus from $74.00 to $108.00. They now have a "buy" rating on the stock.
Low
Report
Soleno Therapeutics, Inc. (NASDAQ: SLNO) had its price target raised by analysts at Stifel Nicolaus from $74.00 to $108.00. They now have a "buy" rating on the stock.
3/28
08:49 am
slno
Soleno Therapeutics, Inc. (NASDAQ: SLNO) had its "buy" rating re-affirmed by analysts at Guggenheim.
Medium
Report
Soleno Therapeutics, Inc. (NASDAQ: SLNO) had its "buy" rating re-affirmed by analysts at Guggenheim.
3/28
04:42 am
slno
Why Soleno Therapeutics Inc. (SLNO) Surged On Thursday? [Yahoo! Finance]
Low
Report
Why Soleno Therapeutics Inc. (SLNO) Surged On Thursday? [Yahoo! Finance]
3/27
02:12 pm
slno
Soleno Therapeutics, Inc. (NASDAQ: SLNO) had its price target raised by analysts at Laidlaw from $75.00 to $105.00. They now have a "buy" rating on the stock.
Low
Report
Soleno Therapeutics, Inc. (NASDAQ: SLNO) had its price target raised by analysts at Laidlaw from $75.00 to $105.00. They now have a "buy" rating on the stock.
3/27
10:20 am
slno
Soleno Surges Into Breakout On Hard-Won Obesity-Tied Approval, Pulling Aardvark Higher [Yahoo! Finance]
Low
Report
Soleno Surges Into Breakout On Hard-Won Obesity-Tied Approval, Pulling Aardvark Higher [Yahoo! Finance]
3/27
09:23 am
slno
Soleno Therapeutics, Inc. (NASDAQ: SLNO) had its price target raised by analysts at Cantor Fitzgerald from $67.00 to $123.00. They now have an "overweight" rating on the stock.
Low
Report
Soleno Therapeutics, Inc. (NASDAQ: SLNO) had its price target raised by analysts at Cantor Fitzgerald from $67.00 to $123.00. They now have an "overweight" rating on the stock.
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
4/2
05:38 pm
slno
Form 4 SOLENO THERAPEUTICS INC For: Apr 01 Filed by: Hirano Patricia C
Low
Report
Form 4 SOLENO THERAPEUTICS INC For: Apr 01 Filed by: Hirano Patricia C
4/1
04:17 pm
slno
Form 144 SOLENO THERAPEUTICS INC Filed by: Hirano Patricia C
Medium
Report
Form 144 SOLENO THERAPEUTICS INC Filed by: Hirano Patricia C
3/31
08:01 pm
slno
Form SCHEDULE 13G/A SOLENO THERAPEUTICS INC Filed by: Vivo Opportunity Fund Holdings, L.P.
Medium
Report
Form SCHEDULE 13G/A SOLENO THERAPEUTICS INC Filed by: Vivo Opportunity Fund Holdings, L.P.
3/31
07:25 pm
slno
Form 4 SOLENO THERAPEUTICS INC For: Mar 28 Filed by: Pauls Matthew
Medium
Report
Form 4 SOLENO THERAPEUTICS INC For: Mar 28 Filed by: Pauls Matthew
3/31
07:23 pm
slno
Form 4 SOLENO THERAPEUTICS INC For: Mar 27 Filed by: Yen Kristen
Medium
Report
Form 4 SOLENO THERAPEUTICS INC For: Mar 27 Filed by: Yen Kristen
3/31
07:21 pm
slno
Form 4 SOLENO THERAPEUTICS INC For: Mar 27 Filed by: Manning Meredith
Medium
Report
Form 4 SOLENO THERAPEUTICS INC For: Mar 27 Filed by: Manning Meredith
3/31
07:20 pm
slno
Form 4 SOLENO THERAPEUTICS INC For: Mar 27 Filed by: Mackaness James H
Medium
Report
Form 4 SOLENO THERAPEUTICS INC For: Mar 27 Filed by: Mackaness James H
3/31
07:19 pm
slno
Form 4 SOLENO THERAPEUTICS INC For: Mar 27 Filed by: Huang Michael F.
Medium
Report
Form 4 SOLENO THERAPEUTICS INC For: Mar 27 Filed by: Huang Michael F.
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
10/23
Soleno Therapeutics Announces Pricing of $13.4 Million Public Offering of Common Stock
34.8%
12/23 Soleno Therapeutics Inc (NASDAQ: SLNO) is now covered by analysts at Oppenheimer Holdings Inc.. They set an "outperform" rating and a $10.00 price target on the stock. 21.2%
11/27 Form 4 SOLENO THERAPEUTICS INC For: Nov 26 Filed by: Vivo Ventures Fund V, L.P. 18.5%
2/14 Form SC 13G/A SOLENO THERAPEUTICS INC Filed by: FEINBERG LARRY N 17.9%
10/2 Soleno Therapeutics Announces Positive Outcome from Second Planned Data Safety Monitoring Board Review of Phase III DESTINY PWS Clinical Trial of DCCR in Prader-Willi Syndrome 17.1%
1/21 Form S-8 SOLENO THERAPEUTICS INC 14.7%
12/9 Form SC 13D/A SOLENO THERAPEUTICS INC Filed by: Vivo Ventures V, LLC 10.7%
11/13 Q3/2019 9/30/2019 EPS 0.030 ZacksConsensus N/A ActVsEst N/A - N/A 10.0%
6/11 Form S-3 SOLENO THERAPEUTICS INC 9.5%
10/28 Form 4 SOLENO THERAPEUTICS INC For: Oct 24 Filed by: Vivo Ventures Fund V, L.P. 9.3%
12/23 Soleno Therapeutics Inc (NASDAQ: SLNO) is now covered by analysts at Oppenheimer Holdings Inc.. They set an "outperform" rating and a $10.00 price target on the stock. 21.2%
11/27 Form 4 SOLENO THERAPEUTICS INC For: Nov 26 Filed by: Vivo Ventures Fund V, L.P. 18.5%
2/14 Form SC 13G/A SOLENO THERAPEUTICS INC Filed by: FEINBERG LARRY N 17.9%
10/2 Soleno Therapeutics Announces Positive Outcome from Second Planned Data Safety Monitoring Board Review of Phase III DESTINY PWS Clinical Trial of DCCR in Prader-Willi Syndrome 17.1%
1/21 Form S-8 SOLENO THERAPEUTICS INC 14.7%
12/9 Form SC 13D/A SOLENO THERAPEUTICS INC Filed by: Vivo Ventures V, LLC 10.7%
11/13 Q3/2019 9/30/2019 EPS 0.030 ZacksConsensus N/A ActVsEst N/A - N/A 10.0%
6/11 Form S-3 SOLENO THERAPEUTICS INC 9.5%
10/28 Form 4 SOLENO THERAPEUTICS INC For: Oct 24 Filed by: Vivo Ventures Fund V, L.P. 9.3%
TOP News Decliners
3/12
Soleno Therapeutics Inc (NASDAQ: SLNO) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating.
-17.5%
8/3 Soleno Therapeutics Inc (NASDAQ: SLNO) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $2.25 price target on the stock. -12.4%
12/26 Soleno Therapeutics Inc (NASDAQ: SLNO) was downgraded by analysts at ValuEngine from a "hold" rating to a "sell" rating. -10.7%
1/24 Form 4 SOLENO THERAPEUTICS INC For: Jan 23 Filed by: Yen Kristen -9.3%
7/25 Soleno Therapeutics Provides Update on Ongoing DESTINY PWS Phase III Trial of DCCR in Prader-Willi Syndrome -8.9%
3/11 Soleno Therapeutics to Present at the 30th Annual Oppenheimer Healthcare Conference -8.8%
3/4 Form 10-K SOLENO THERAPEUTICS INC For: Dec 31 -8.3%
2/22 Soleno Therapeutics Inc (NASDAQ: SLNO) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $3.75 price target on the stock. -7.0%
8/21 Soleno Therapeutics Inc (NASDAQ: SLNO) was downgraded by analysts at ValuEngine from a "buy" rating to a "hold" rating. -6.8%
12/11 Soleno Therapeutics Inc (NASDAQ: SLNO) was downgraded by analysts at ValuEngine from a "buy" rating to a "hold" rating. -6.0%
8/3 Soleno Therapeutics Inc (NASDAQ: SLNO) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $2.25 price target on the stock. -12.4%
12/26 Soleno Therapeutics Inc (NASDAQ: SLNO) was downgraded by analysts at ValuEngine from a "hold" rating to a "sell" rating. -10.7%
1/24 Form 4 SOLENO THERAPEUTICS INC For: Jan 23 Filed by: Yen Kristen -9.3%
7/25 Soleno Therapeutics Provides Update on Ongoing DESTINY PWS Phase III Trial of DCCR in Prader-Willi Syndrome -8.9%
3/11 Soleno Therapeutics to Present at the 30th Annual Oppenheimer Healthcare Conference -8.8%
3/4 Form 10-K SOLENO THERAPEUTICS INC For: Dec 31 -8.3%
2/22 Soleno Therapeutics Inc (NASDAQ: SLNO) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $3.75 price target on the stock. -7.0%
8/21 Soleno Therapeutics Inc (NASDAQ: SLNO) was downgraded by analysts at ValuEngine from a "buy" rating to a "hold" rating. -6.8%
12/11 Soleno Therapeutics Inc (NASDAQ: SLNO) was downgraded by analysts at ValuEngine from a "buy" rating to a "hold" rating. -6.0%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: